Our goal is to establish the pHLIP® Platform Technology as a standard of care for targeted therapeutics.
Our business strategy is to develop pHLIP® applications ourselves and through partnership and collaboration.
Cybrexa Therapeutics holds exclusive rights for the development of therapeutic agents for the treatment of cancers in humans based on use of pH-sensitive peptides, pHLIP®, for targeted delivery of a few cytotoxic molecules.
pHLIP, Inc. has exclusive rights to a comprehensive and growing IP portfolio.